194.18
Real-Time Quote
 +9.20 / +4.97%
Today’s Change
129.58
Today|||52-Week Range
264.98
+37.43%
Year-to-Date
Shire (SHPG) is Oversold: Can It Recover? - Tale of the Tape
10:53am / Zacks.com
Shire (SHPG) Shares Crash on Concerns Over AbbVie Buyout - Analyst Blog
Oct 16 / Zacks.com
Earnings Scheduled For October 24, 2014
6:08am / Benzinga
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Up 14.7% - Tale of the Tape
Oct 16 / Zacks.com
Stocks: 4 things to know before the open
5:09am / CNNMoney.com
3 Reasons AbbVie's Stock Could Rise
Oct 16 / MotleyFool.com
Should You Sell Shire (SHPG) Before Earnings? - Tale of the Tape
Oct 23 / Zacks.com
Stocks: 5 things to know before the open
Oct 16 / CNNMoney.com
Benzinga's M&A Chatter for Tuesday October 21, 2014
Oct 21 / Benzinga
 $55 billion deal halted by tax dodge crackdown
Oct 15 / CNNMoney.com
AbbVie Drops Shire Deal, Announces Buyback, Ups Dividend - Analyst Blog
Oct 21 / Zacks.com
Sucampo/Takeda Amend Collaboration Agreement for Amitiza - Analyst Blog
Oct 15 / Zacks.com
Avoid the Crowd
Oct 21 / TheStreet.com
Concert Pharmaceuticals Announces Positive CTP-354 Data - Analyst Blog
Oct 15 / Zacks.com
Some Potential Targets for Shire to Buy With $1.6B in Free Money
Oct 21 / TheStreet.com
AbbVie Reconsiders Shire Acquisition Due to New Tax Rules - Analyst Blog
Oct 15 / Zacks.com
#PreMarket Primer: Tuesday, October 21: China's Third Quarter Growth Disappoints
Oct 21 / Benzinga
Johnson & Johnson Earnings: Showing Surprising Weakness
Oct 15 / MotleyFool.com
European Stocks Rise as Corporate Earnings Overshadow Macro Concerns
Oct 21 / TheStreet.com
Stocks: 4 things to know before the open
Oct 15 / CNNMoney.com
Must Watch Stocks For October 21, 2014
Oct 21 / Benzinga
AbbVie's Humira Positive in Late-Stage Skin Disease Study - Analyst Blog
Oct 14 / Zacks.com
Benzinga's M&A Chatter for Monday October 20, 2014
Oct 20 / Benzinga
J&J Beats Q3 Earnings on Strong Drug Sales, Ups View - Analyst Blog
Oct 14 / Zacks.com
Announcement Of Termination Of Proposed AbbVie And Shire Transaction
Oct 20 / Benzinga
Novartis Releases Data on Secukinumab for Plaque Psoriasis - Analyst Blog
Oct 13 / Zacks.com
Sanofi and Regeneron Dose Patients in Dupilumab Study - Analyst Blog
Oct 20 / Zacks.com
Celgene's Otezla Encourages in Plaque Psoriasis at EADV - Analyst Blog
Oct 13 / Zacks.com
IBM's Report Weighs On The Dow, Apple Helps Boost The Nasdaq, S&P 500 Extends Winning...
Oct 20 / Benzinga
Gilead's All-Oral Combo HCV Drug Harvoni Cleared by FDA - Analyst Blog
Oct 13 / Zacks.com
3 Stocks I'll Buy if the Market Crashes
Oct 20 / MotleyFool.com
Egalet (EGLT) Shows Strength: Stock Moves 7.1% Higher - Tale of the Tape
Oct 13 / Zacks.com
Benzinga's Weekend M&A Chatter
Oct 19 / Benzinga
Strength Seen in Sucampo (SCMP): Stock Rises 9.4% - Tale of the Tape
Oct 13 / Zacks.com
Benzinga Weekly Preview: Earnings Season Is In Full Swing
Oct 19 / Benzinga
Vertex Pharmaceuticals (VRTX) Updates on Kalydeco Studies - Analyst Blog
Oct 10 / Zacks.com
Astellas Files for Amendment of Isavuconazole Study Protocol - Analyst Blog
Oct 17 / Zacks.com
Shire's NDA on ADHD Candidate SHP465 Suffers Setback - Analyst Blog
Oct 10 / Zacks.com
Roche Reports Strong Sales Results for 9 Months of 2014 - Analyst Blog
Oct 17 / Zacks.com
 

To view my watchlist

Not a member yet?

Sign up now for a free account

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2014 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2014. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2014 and/or its affiliates.